Connor, Clark & Lunn Investment Management (CC&L)
AKRO

Connor, Clark & Lunn Investment Management (CC&L)’s Akero Therapeutics AKRO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,328
Closed -$2.21M – 1487
2025
Q2 		$2.21M Buy
+41,328
New +$1.88M 0.01% 827
2024
Q4 		– Sell
-10,159
Closed -$291K – 1394
2024
Q3 		$291K Sell
10,159
-59,836
-85% -$1.56M ﹤0.01% 1247
2024
Q2 		$1.64M Sell
69,995
-32,607
-32% -$697K 0.01% 708
2024
Q1 		$2.59M Buy
102,602
+92,587
+924% +$2.22M 0.01% 608
2023
Q4 		$234K Sell
10,015
-8,048
-45% -$159K ﹤0.01% 1230
2023
Q3 		$914K Sell
18,063
-5,675
-24% -$264K ﹤0.01% 848
2023
Q2 		$1.11M Buy
+23,738
New +$1.09M 0.01% 769
2022
Q4 		– Sell
-70,253
Closed -$2.39M – 1188
2022
Q3 		$2.39M Buy
70,253
+39,162
+126% +$599K 0.02% 460
2022
Q2 		$294K Buy
+31,091
New +$324K ﹤0.01% 867

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AKRO Position: Q3 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 41,328 shares — an estimated $2.21M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AKRO in Q2 2022 and held it in 9 quarters. The position peaked at $2.59M in Q1 2024. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 41,328 Akero Therapeutics shares in Q3 2025, an estimated $2.21M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Akero Therapeutics in Q2 2022 and held it in 9 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Akero Therapeutics position peaked at $2.59M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2025, filed 13 Nov 2025.